Ligand validation:6JY7

OLA: OLEIC ACID

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6JY7_OLA_A_304	46%	46%	0.121	0.91	0.95	1.15	1	2	1	0	70%	0.7
6JY7_OLA_A_309	42%	59%	0.109	0.915	0.98	0.62	1	-	0	0	50%	0.5
6JY7_OLA_A_305	37%	57%	0.173	0.868	0.8	0.86	1	-	1	0	100%	1
6JY7_OLA_A_306	29%	52%	0.164	0.838	0.83	1.01	1	2	0	0	90%	0.9
6JY7_OLA_A_310	27%	76%	0.148	0.923	0.33	0.6	-	-	1	0	30%	0.3
6JY7_OLA_A_311	26%	69%	0.148	0.888	0.34	0.84	-	-	0	0	45%	0.45
6JY7_OLA_A_312	18%	48%	0.188	0.876	0.7	1.29	-	2	0	0	45%	0.45
6JY7_OLA_A_308	18%	43%	0.103	0.76	1.04	1.16	1	1	0	0	60%	0.6
6JY7_OLA_A_307	17%	53%	0.175	0.846	0.66	1.14	-	-	1	0	50%	0.5
6JY7_OLA_A_313	16%	49%	0.165	0.828	0.73	1.24	-	1	0	0	45%	0.45
6JY7_OLA_A_314	4%	60%	0.219	0.688	0.81	0.71	1	-	0	0	55%	0.55
5G28_OLA_A_1271	60%	64%	0.097	0.898	0.77	0.61	1	-	0	0	90%	0.9
7CRL_OLA_A_305	49%	39%	0.134	0.878	1	1.39	1	2	1	0	100%	0.7582
7CRJ_OLA_A_305	48%	49%	0.13	0.87	0.9	1.05	1	2	0	0	100%	0.8453
6JYC_OLA_A_304	47%	47%	0.132	0.923	0.95	1.1	1	1	2	0	70%	0.7
6JYB_OLA_A_304	45%	46%	0.119	0.904	0.94	1.15	1	2	1	0	70%	0.7
6DJ6_OLA_B_402	92%	68%	0.081	0.971	0.55	0.69	-	-	0	0	100%	1
1LFO_OLA_A_128	79%	59%	0.097	0.943	0.78	0.79	1	-	0	0	100%	1
6E12_OLA_B_301	65%	45%	0.13	0.932	1.01	1.12	1	2	2	0	100%	1
8GEW_OLA_A_202	64%	57%	0.138	0.938	0.69	0.94	-	2	0	0	100%	0.44
5IU4_OLA_A_2406	64%	62%	0.105	0.903	0.69	0.75	-	1	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.